---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-005393"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2023-04-03T23:59:59+00:00"
generated_at: "2026-06-17T07:15:49.816332+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Xilio appoints Kevin Brennan as SVP, Finance and Accounting, principal financial officer

## Summary
- Kevin Brennan joined Xilio on March 30, 2023 as SVP, Finance and Accounting and principal financial/accounting officer.
- Brennan receives annual base salary of $370,000, target bonus of 35% of base salary.
- Granted stock option to purchase 55,000 shares; vests 25% on first anniversary, 75% monthly over 3 years.
- Board adopted amended and restated bylaws updating stockholder meeting procedures and universal proxy rules.
- Bylaw amendments also include enhanced advance notice disclosure requirements and technical changes.

## SEC filing metadata
- accession: 0001558370-23-005393
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2023-04-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000155837023005393/0001558370-23-005393-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000155837023005393/xlo-20230328x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-005393
- JSON: https://secwatch.observer/filing/0001558370-23-005393.json
- Plain text: https://secwatch.observer/filing/0001558370-23-005393.txt

## Key facts
- Executive change
  Kevin Brennan was appointed as Senior Vice President, Finance and Accounting at Xilio Therapeutics, Inc..
  - Action: appointed
  - Role: Senior Vice President, Finance and Accounting
  source text: On March 30, 2023, Kevin Brennan joined Xilio Therapeutics, Inc. (the “Company”) as Senior Vice President, Finance and Accounting, and the board of directors (the “Board”) of the Company appointed Mr. Brennan to serve as the Company’s principal financial officer and principal accounting officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840233/000155837023005393/0001558370-23-005393-index.htm
- Governance Changes
  Xilio Therapeutics, Inc.: Adopted Second Amended and Restated Bylaws to amend stockholder meeting procedures, voting list requirements, adjournment procedures, advance notice requirements, proxy card color, eliminate director compensation provision, and make technical and conforming changes (effective 2023-03-28).
  - Change: bylaw amendment
  - Effective: 2023-03-28
  source text: On March 28, 2023, the Board adopted amended and restated bylaws of the Company (as amended and restated, the “Second Amended and Restated Bylaws”), effective immediately
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840233/000155837023005393/0001558370-23-005393-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.